We are international
• advocacy   TEXT SIZE   
Advocacy Update    back

ASCO 2013: Dr. Ghobrial - Phase I study of TH-302, an investigational hypoxia-targeted drug, and dex in patients with RRMM

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

 related articles